Is it realistic that given the high expectations for cyprotex that it could reach 3 per share. Partnerships with the big pharma co's could make these shoot north?

with results due Wed and the prognosis being that these will surprise, looking at past performance though as stated in the adverts can't go on it. I will say that over the coming period these will begin a rapid ascent if not in the next few days surely in the comming months.

The results have certainly surprised,they are well and above expectations with profit margins up by 100%,turnover up by 100%, and tplenty of cash to keep them going for a long time.Neither do they have there eggs all in one basket with reliance on no-one company to provide revenue.

Press Release 9 March 2005
Cyprotex PLC
('Cyprotex' or 'the Company')

Preliminary Results for year ended 31 December 2004

Cyprotex PLC, a drug discovery technology and information company, today reports
its preliminary results for the year ended 31 December 2004.



Revenue increased over 100% to 2.12 million from 1.05 million

Gross profits more than doubled to 1.7 million up from 0.8 million

Gross margins rose to 80%, compared with 76%

Cash resources were carefully guarded. Year end net cash amounted to
1.84m, compared with 0.49m for the previous year, despite
significant capital investment in new laboratory capabilities

Basic loss per share almost halved to 1.04p compared with 2.05p

The customer base, ranging from global pharmaceutical groups to the
smallest biotechnology companies, continued to expand rapidly; the
largest of which contributed less than 14% of total revenues in 2004
http://www.uk-wire.com/cgi-bin/articles/200503090700154991J.html

Just in case anyone missed it.....

"Cyprotex slashes losses
MoneyAM
Cyprotex narrowed its pretax loss in the first half to June as it announced a 58% rise in revenues.

The first half pretax loss narrowed to 487,627 from 831,867 a year earlier, while revenues rose to 1.4m from 886,238.

Chairman and CEO said 'significant progress' had been made during the half-year towards achieving some major goals set at the beginning of the year, adding 'this bodes well for the full year'.

The company noted that 'somewhat earlier than expected', it is trading cash flow positive on a single monthly basis, after a significant expansion that was largely paid for during 2004.

Cyprotex said its Cloe Screen hERG channel inhibition assay is now fully integrated into the automated high throughput system, and that restructuring of its metabolite profiling and identification is now well advanced.

It said additional offerings of both in-vitro safety toxicology and new assay development will be commercialised during the second half.

The company added it has entered into a 'significant long-term contract' for its integrated Cloe offering with the US pharmaceutical company Sepracor Inc."

Hasn't done much for the sp today despite several positive rns's!!!

-ce la vie!

very positive interims.

"Drug discovery technology company Cyprotex has reached some significant milestones this year and with a key deal with the worlds largest biotech company in the bag, the future looks interesting."

By: Joanne Wallen, Associate Editor (Citywire)
http://www.citywire.co.uk/News/NewsArticle.aspx?VersionID=76456

They also issued two other RNS ref a significant long term contract with Sepracor who are a large pharma based in Masachusets. As of June 30, 2005, Sepracor had approximately $920 million in cash and short- and long-term investments.

http://www.sepracor.com

Additionally the appointment of Dr Darwin Cheney as Chief Scientific Officer of the Company.Dr Cheney will be responsible for all laboratory operations at Cyprotex. Dr. David Leahy, who held the position previously, becomes Chief Technical Officer with specific responsibility for the development of new products and services for the Company.
Dr Cheney has worked for many years in laboratory operations management as Executive Director of Contract Research for In Vitro Technologies and as Director of Neuroscience and Cardiovascular Research and Executive Director of Clinical Operations and Statistics at CIBA-GEIGY Pharmaceuticals. He has published 116 scientific papers and brings over 25 years' experience in the discovery and development of pharmaceutical compounds.
http://www.cyprotex.com/news/2005/news_2005_08_17_2.html

So why do people continually throw money away instead of looking for growth and value is beyond me.Perhaps they like a flutter if that's the case there are plenty of bookies about.

Just had to top up up at 10.6p.

Getting a little overweight in this now, but with the limited downside and good news not far away I am not concerned.

With the recent issue of animal experimentation coming to the fore, much as I dislike the violent antics of the ALF, the issue of live experimentation will be raised in the public domain and thereby improve potential sales of CRX products.
Not worried

Interesting investment.

Could raise the price.




Cyprotex PLC
27 January 2006


Press Release 27 January 2006

Cyprotex Plc

('Cyprotex' or 'the Company')

Notification of substantial shareholding


Cyprotex PLC (AIM: CRX), announces that it received notification on 27 January
2006, that, as of the same date, Bank of Scotland has beneficially acquired
27,115,098 ordinary shares in the Company. This represents the total holding of
Bank of Scotland in the capital of the Company and equates to 19.6% of the
issued share capital.

going well to day results out on wednesday and hopefully a contract from japan

now no1 on the %leader board up 28%

With bank of scotland holding 19.06%
Nordan holdings 21.30%
Intercapital 16.51%
Artems fund mangagers 6.09%
Close finsbury asset management 6.91%
Bnp paribas 3.99%
Deutsche asst management 3.06%
Total of 83% of share capital leaves 20.50 million in circulation, when it does move it will be fast on small volume.

Cyprotex Trading Statement

RNS Number:5916F
Cyprotex PLC
12 October 2007

Cyprotex PLC
(the "Group" or "Cyprotex")


NEWS

12 October 2007

Trading Update : Building Confidence

The Director's confidence with Cyprotex's core operations continued to build
during the third quarter of 2007. The Group enters the final three months of
its year on an optimistic note.

Historically the final quarter has been the strongest period of Cyprotex's
financial year. Moreover, management is pleased to confirm that its customer
base has continued to expand rapidly. Included within the high number of new
MSA (Master Services Agreements) recently signed, and taking the Group's 'active
customer list' beyond 150 pharmaceutical and biotech companies, are several
international majors. Strict confidentiality agreements preclude Cyprotex from
naming individual clients, but the company can now confirm it is currently
contracted to work for six out of the world's 'top ten' global pharmaceutical
companies. The scale and visibility that strong working relationships with such
partners are capable of providing, is key to proving Cyprotex's business plan.
The management is pleased to report an exceptional level of repeat business,
while also being asked to tenders for more long-term contract work as well as
project specific collaborations.

Cyprotex presently holds an adequate cash resource whilst also retaining a
significant, unused banking facility. Based on current momentum, management
sees the opportunity for modest cash generation to expand this 'cushion' still
further during the final three months of the 2007.

For further information:

Cyprotex PLC
Robert Morrison Atwater, CEO
Russell Gibbs, CFO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Numura Code Securities Limited
Charles Walker, Corporate Finance
Tel: +44 (0)20 7776 1200
cew@nomuracode.com
www.nomuracode.com

Media Enquires:

WMC Communications
Simon Miller
Tel: +44 (0)20 7930 9030
simon.miller@wmccommunications.com


This information is provided by RNS
The company news service from the London Stock Exchange
END

Press Release 23 November 2007


Cyprotex PLC
("Cyprotex" or "the Company")


Director share purchases

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company
was notified today that Robert Morrison Atwater, the Chairman and Chief
Executive of the Company purchased a total of 175,000 ordinary shares of 0.1p
each in the Company on 22 November 2007 at the following price per share: 75,000
shares at 3.74p; 50,000 shares at 3.78p; and 50,000 shares at 4.00p. Robert
Morrisson Atwater now has a total interest of 1,610,000 ordinary shares in the
Company, which represents 1.16% of the issued share capital of the Company.


- Ends -


For further information:

Cyprotex PLC
Mark Warburton Tel: +44 (0) 1625 505100
iir@cyprotex.com www.cyprotex.com



This information is provided by RNS
The company news service from the London Stock Exchange
END

MACD Indicator turning more towards positive (blue line over red line) for the first time in five weeks. Breakout over 5p looms IMO and Level 2 backs that up. Level 2 closed positive at 3 v 2. 2 MMs on 4.75p, then one on 5p and 2 have already taken positions on 5.25p. Wouldn't be surprise to see more director buying at these low levels.

L2 is 3 v 1...last MM on 4.75p and then 2 on 5p and 2 on 5.25p...Will get more director buying confirmation this week and then breakout over 5p.

4.00-5.00 pence, Level 2 is 1 v 3. On its way to 6p IMO.

4.25-5.00p, L2 is 1 v 1.

4.25-5.25p, L2 is 2 v 4.

4.25-5.25p, L2 is 2 v 4. Should settle here and then push towards 6p tomorrow IMO.

Breakout: MACD Indicator gone positive for the first time in a month.

Another pump and dump by active/chancer6 on three different bulletin
boards today.

His sale of 83062 shares went through late on so this will ensure the
posts will stop until the next pump and dump.

Where's a plumber when you need one?

;-)))